This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=97 http://www.lsis.com/goto/r97/rss 2012-02-05T11:11:01+01:00 text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=97 United States Patent: 8101590 |-| Title: 9-aminocarbonylsubstituted derivatives of glycylcyclines |-| Inventors: Sum; Phaik-Eng (Pomona, NY), Mansour; Tarek Suhayl (New City, NY), How; David Brian (Nyack, NY), Hopper; Darrin William (New York, NY), Vera; Matthew Douglas (Royersford, PA), Sabatini; Joshua James (White Plains, NY), Shim; Jaechul (Oakland, NJ) |-| Assignee: Wyeth LLC (Madison, NJ) |-| This invention provides compounds of Formula I having the structure #STR00001# where R.sub.1, (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=97 United States Patent: 8101194 |-| Title: Immunogenic compositions for the prevention and treatment of meningococcal disease |-| Inventors: Zlotnick; Gary W. (New Windsor, NY), Fletcher; Leah Diane (Geneseo, NY), Farley; John Erwin (Chapel Hill, NC), Bernfield; Liesel A. (Pittsford, NY), Zagursky; Robert J. (Victor, NY), Metcalf; Benjamin J. (Rochester, NY) |-| Assignee: Wyeth LLC (Madison, NJ) |-| The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 BACKGROUND: Tigecycline, a broad-spectrum antibiotic used for treating serious bacterial infections in adults, may be suitable for pediatric use once an appropriate dosage is determined. OBJECTIVE: The aim of this study was to assess the pharmacokinetic (PK) properties, safety profile, and descriptive efficacy of tigecycline. METHODS: In this Phase II, multicenter, open-label clinical trial, children aged 8 to 11 years with community-acquired pneumonia (CAP), complicated intra-abdominal (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 The present study investigated the potential role for activation of PPAR? and CAR/PXR by potassium PFOS (K(+)PFOS) with respect to the etiology of hepatic hypertrophy and hepatocellular adenoma in rats. Male Sprague-Dawley rats were fed K(+)PFOS (20 or 100ppm) for either 1, 7, or 28 days. Wyeth 14,643 (Wy 14,643, 50ppm) and phenobarbital (PB, 500ppm) were the controls for PPAR? and CAR/PXR activation, respectively. Measurements included: plasma ALT, AST, cholesterol, triglycerides, and (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=97 United States Patent: 8092798 |-| Title: Method of increasing trabecular bone density in a patient in need thereof by an antibody against GDF-8 |-| Inventors: Aghajanian; Jane (Belgrade, ME), Dunham, legal representative; William J. (Belgrade, ME), Wolfman; Neil M. (Dover, MA), O'Hara; Denise (Reading, MA), Davies; Monique V. (Harpswell, MA), Veldman; Geertruida M. (Sudbury, MA), Bridges; Kristie Grove (Maynard, MA), Whittemore; Lisa-Anne (East Walpole, MA), Khurana; Tejvir S. (Narberth, PA), (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=97 South San Francisco, CA, January 5, 2012 - Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced that Pfizer Inc. has initiated a Phase 1 clinical trial for PF-05280602, an investigational proprietary, engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences. PF-05280602 has been engineered to provide improved acute and prophylactic treatment for hemophilia A & B patients with inhibitors. The IND (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=97 United States Patent: 8088905 |-| Title: Nucleic acids encoding antibodies against PD-1 |-| Inventors: Collins; Mary (Natick, MA), Wood; Clive R. (Boston, MA), Carreno; Beatriz M. (Acton, MA), Luxenberg; Deborah (Melrose, MA), Jussif; Jason (Salem, NH), Carter; Laura L. (Medford, MA), Bennett; Frances K. (Sudbury, MA), Valge-Archer; Viia (Little Abbington, GB), Andrews; John (Little Hadham Ware, GB), Russell; Caroline (Herts, GB) |-| Assignee: Wyeth (Madison, NJ) MedImmune Limited (GB) |-| (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 Src-null mice have higher bone mass due to decreased bone resorption and increased bone formation, whereas Abl-null mice are osteopenic, due to decreased bone formation. Compound I, a potent inhibitor of Src in an isolated enzyme assay (IC(50) 0.55 nM) and a Src-dependent cell growth assay, with lower activity on equivalent Abl-based assays, potently, but biphasically, accelerated differentiation of human mesenchymal stem cells to an osteoblast phenotype(1-10 nM). Compound I (? 0.1 nM) (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 The neuropeptide cholecystokinin (CCK) is abundant in the CNS and is expressed in a subset of inhibitory interneurons, particularly in their axon terminals. The expression profile of CCK undergoes numerous changes in several models of temporal lobe epilepsy. Previous studies in the pilocarpine model of epilepsy have shown that CCK immunohistochemical labeling is substantially reduced in several regions of the hippocampal formation, consistent with decreased CCK expression as well as selective (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=97 NEWPORT BEACH, CA, DECEMBER 13, 2011: CureDuchenne, a national nonprofit that funds research to find a cure for Duchenne muscular dystrophy, today announced the appointment of Dr. Michael G. Kelly as Chief Scientific Officer, a key scientific position within the Duchenne community. Kelly, a senior pharmaceutical executive, brings more than 25 years experience in drug discovery and development to the organization. He will help advance drug development programs and help identify new drug targets (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=97 Pfizer Inc. (PFE) must pay $72.6 million in damages to three women who said they developed breast cancer after taking the company s menopause drugs, a Philadelphia jury decided. Jurors today in state court deliberated over two days before finding hormone-replacement drugs made by Pfizer s Wyeth and Pharmacia Upjohn units were responsible for Susan Elfont, Bernadette Kalenkoski and Judy Mulderig developing cancer. The panel awarded Elfont $20 million in compensatory damages; Kalenkoski, $27.85 (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=97 United States Patent: 8071112 |-| Title: Compositions and methods of use of ORF-1358 from beta-hemolytic streptococcal strains |-| Inventors: Murphy; Ellen (City Island, NY), Braunstein; Emily Mara (New York, NY), Garcia-Hand; Dorys (Croton-on-Hudson, NY), Anderson; Annaliesa Sybil (Upper Saddle River, NJ), Dodge; Ingrid Lea (Cornwall, NY), Rojas; Eduardo Arturo (Briarcliff Manor, NY) |-| Assignee: Wyeth LLC (Madison, NJ) |-| The present invention relates to polynucleotides encoding (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=97 CAMBRIDGE, MA-(Marketwire - December 05, 2011) - Highlighted Links Radius Website C. Richard Lyttle retires as President and CEO and will serve as interim CSO Kurt Graves appointed Chairman of the Board Louis Brenner appointed CMO Radius Health, Inc. ("Radius") announced today the appointment of Michael S. Wyzga as President and Chief Executive Officer and a member of the Board of Directors, effective with the retirement of C. Richard Lyttle, PhD from the company and the Radius Board of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 In the 1990s, drug companies focused their resources on chemistry-based proprietary blockbuster compounds (small molecules) for chronic diseases that could bring in several billion dollars in a short period of time. Since then, the focus has turned to biologics (proteins/high MW molecules) such as anticancer agents, antibodies, and so on. Vaccines, in contrast, are a rather slow-growing market, administered only a few times per patient, low priced, and often undifferentiated. Due to the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=97 Pfizer Inc. s Wyeth unit and Teva Pharmaceuticals USA Inc. were accused by a group of prescription drug retailers of illegally keeping a generic version of the Effexor XR antidepressant off the market. œWyeth engaged in an overarching anticompetitive scheme to prevent and delay the approval and marketing of generic versions of Effexor XR,  the retailers, including Walgreen Co. and Kroger Co., said in a complaint filed Nov. 30 in federal court in Trenton, New Jersey. The retailers allege (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 JX-594 is an oncolytic virus derived from the Wyeth vaccinia strain that causes replication-dependent cytolysis and antitumor immunity. Starting with a cross-examination of clinical-trial samples from advanced hepatocellular carcinoma patients having high levels of aldosterone and virus amplification in JX-594 treatment, we investigated the association between virus amplification and aldosterone in human cancer cell lines. |-| Korean J Hepatol. |-| Lee HJ, Rho J, Gui SR, Kim MK, Lee YK, Lee (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=97 Pharmaceutical giant Pfizer Inc. said last week it reached agreements-in-principle with U.S. authorities to resolve a foreign bribery investigation. Mark Lennihan/Associated PressThe company said in a securities filing it expects to enter into and announce final agreements with the Securities and Exchange Commission and the Justice Department by the end of the year. The alleged misconduct has to do with œpotentially improper payments made by certain Pfizer and Wyeth subsidiaries  connected (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 Alzheimer's disease is characterized by the deposition of amyloid plaques in the brain. The major components of these plaques are ?-amyloid (A?) peptides. The CSF concentration of these peptides can therefore provide a valuable biomarker for potentially predicting the state of disease and/or monitoring the efficacy of a drug aiming to inhibit the formation of amyloid plaques. Although the concentration of a given peptide in CSF can easily be measured by ELISA methods, few methods are able to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/200bac/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: Sweden" report to their offering. The Swedish pharmacy monopoly has been deregulated, leading to greater competition and a downward pressure on the price of pharmaceuticals. The number of pharmacies is likely to continue to rise rapidly in 2011, and slow down and stabilise from 2012 onwards. In 2010, the largest (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/06c9de/the_global_pain_th) has announced the addition of the "The Global Pain Therapeutics Market: 4th Edition - Market Trends & R&D Insights" report to their offering. The Global Pain Therapeutics Market: 4th Edition - Market Trends & R&D Insights Pain continues to present numerous challenges to the biopharmaceutical industry. According to the American Academy of Pain Medicine, over 76 million Americans (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=97 GHENT, BELGIUM-(Marketwire - November 04, 2011) - Ablynx [Euronext Brussels: ABLX] today announced that it has regained worldwide rights from Pfizer Inc. to develop and commercialise Nanobodies targeting TNF-alpha. These rights include the product ATN-103, for which positive proof-of-concept data from a Phase II trial in rheumatoid arthritis (RA) were announced in May of this year; and the product PF-05230905, which is in Phase I trials. Ablynx will undertake a detailed review of the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 Summary.? Nonacog alfa, a recombinant factor IX (FIX) used for the treatment of haemophilia B, was approved in Europe in 1998. In accordance with European Medicines Agency requirements, a registry study was conducted from 2002 to 2009. A reformulated iso-osmotic version was approved for European use in 2007. This study was conducted to evaluate the safety of nonacog alfa in a usual care setting, and provide clinical trial and postmarketing surveillance data support. This open-label, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 NEW YORK-(BUSINESS WIRE)-Pfizer Inc. (NYSE: PFE): Forward-Looking Information and Factors That May Affect Future Results ($ in millions, except per share amounts) Third-Quarter(4) Year-to-Date(4) 2011 2010 Change 2011 2010 Change Reported Revenues $ 17,193 $ 15,995 7 % $ 50,679 $ 49,703 2 % Adjusted Income(1) 4,820 4,352 11 % 14,354 14,141 2 % Adjusted Diluted EPS(1) 0.62 0.54 15 % 1.81 1.75 3 % Reported Net Income(2) 3,738 866 * 8,570 5,367 60 % Reported Diluted EPS(2) 0.48 0.11 * 1.08 0.66 (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 First human administration of a new chemical entity (NCE) constitutes a critical step in drug development. The primary objective of such a study is the assessment of the shortterm safety and tolerability of single and multiple doses of the NCE in healthy volunteers. Secondary objectives are to obtain preliminary data on the pharmacokinetics and pharmacodynamics using surrogate or biornarkers of the beneficial as well as the adverse effects of the drug. Interpretation of safety data should be (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/443d5b/asia_pacific_pharm) has announced the addition of Venture Planning Group's "Asia Pacific Pharmaceutical Market: Strategic Assessments of Leading Suppliers" report to their extensive offering of pharmaceutical market research publications. Asia Pacific Pharmaceutical Market: Strategic Assessments of Leading Suppliers Venture Planning Group's latest report provides industry executives with (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/ab0ae1/pharmaceutical_dis) has announced the addition of the "Pharmaceutical Distribution in the US: Current and Future Perspectives" report to their offering. Pharmaceutical Distribution in the US: Current and Future Perspectives Comprehensive overview of the business of pharmaceutical distribution in the US. Full analysis of the challenges facing the sector, plus 17 case studies. In the US, the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 DUBLIN-(BUSINESS WIRE)-Elan Corporation, plc today reported its third quarter and first nine months 2011 financial results. Unaudited Non-GAAP Financial Information Adjusted EBITDA œWe are pleased with the financial and commercial progress we have made this quarter. The closing of the EDT deal in particular is transformational for our business, specifically in our ability to address debt and focus appropriate and measured investment in our neuroscience efforts,  said Kelly Martin, chief (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/48a628/pharmaceutical_mar) has announced the addition of the "Pharmaceutical Market Trends, 2010 - 2014: Key market forecasts & growth opportunities 4th Edition" report to their offering. Pharmaceutical Market Trends, 2010 - 2014: Key market forecasts & growth opportunities 4th Edition 4th Edition report provides an excellent overview and analysis of the global pharmaceutical market to the end of 2009 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/3b5e71/mergers_and_acquis) has announced the addition of the "Mergers and Acquisitions in the Pharmaceuticals Sector, 2009: Critical Success Factors for Competing in a Consolidating Market" report to their offering. Mergers and Acquisitions in the Pharmaceuticals Sector, 2009: Critical Success Factors for Competing in a Consolidating Market Explores the merits of mega-deal in contrast to a more measured (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=97 United States Patent: 8044178 |-| Title: Anti-5T4 antibodies and uses thereof |-| Inventors: Boghaert; Erwin R. (Monroe, NY), Damle; Nitin K. (Upper Saddle River, NJ), Hamann; Philip Ross (Thiells, NY), Khandke; Kiran (Nanuet, NY), Kunz; Arthur (New City, NY), Marquette; Kimberly A. (Somerville, MA), Tchistiakova; Lioudmila (Andover, MA), Gill; Davinder (Andover, MA), Sreekumar; Kodangattil (Plainsboro, NJ) |-| Assignee: Wyeth LLC (Madison, NJ) |-| Anti-5T4 antibodies, anti-5T4 antibody/drug (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=97 ScienceDaily (Oct. 20, 2011) With age, forgetfulness and other signs of memory loss sometimes appear, prompting elderly individuals to seek a medical evaluation amid fears that they may be experiencing early symptoms of Alzheimer's disease (AD), the most common type of dementia among Americans aged 65 and older. See Also: Health & Medicine Alzheimer's Research Healthy Aging Chronic Illness Mind & Brain Alzheimer's Dementia Intelligence Reference Dementia Dementia with Lewy bodies Multi-infarct (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=97 With age, forgetfulness and other signs of memory loss sometimes appear, prompting elderly individuals to seek a medical evaluation amid fears that they may be experiencing early symptoms of Alzheimer's disease (AD), the most common type of dementia among Americans aged 65 and older. But even when early memory problems suggest the potential for impending AD, the actual risk is variable. Some patients are at high risk while others are not. The challenge for doctors has long been to (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=97 PRINCETON, N.J., October 18, 2011 Covance Inc. (NYSE: CVD), one of the world s largest and most comprehensive drug development services companies, today announced that Raymond Kaiser, Ph.D., has joined the company as the new Global Science Leader and Vice President for Biotechnology Services. Kaiser will replace Dr. Carl Martin, who will be retiring from this role, after 35 years with Covance. Dr. Kaiser comes to Covance from Merck Research Laboratories in West Point, Pa., where he was (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=97 United States Patent: 8039231 |-| Title: Methods for enhanced production of bone morphogenetic proteins |-| Inventors: Luan; Yen-Tung (Chelmsford, MA), Wang; Wenge (North Chelmsford, MA), Nyberg; Gregg (Westminster, CO), Gomes; Jose Manuel (Chelmsford, MA), Drapeau; Denis (Salem, NH), Cardoza; Terry (Methuen, MA) |-| Assignee: Wyeth LLC (Madison, NJ) |-| Methods and processes for improved recombinant protein production are provided. The methods are useful for production of growth factors, (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=97 United States Patent: 8039469 |-| Title: Triazine compounds as PI3 kinase and mTOR inhibitors |-| Inventors: Venkatesan; Aranapakam Mudumbai (Rego Park, NY), Chen; Zecheng (New City, NY), Dehnhardt; Christoph Martin (New York, NY), Santos; Osvaldo dos (Astoria, NY), Santos; Efren Guillermo Delos (Nanuet, NY), Zask; Arie (New York, NY), Verheijen; Jeroen Cunera (Highland Mills, NY), Kaplan; Joshua Aaron (Nyack, NY), Richard; David James (Warwick, NY), Ayral-Kaloustian; Semiramis (Tarrytown, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 LYON, France & WOODCLIFF LAKE, N.J.-(BUSINESS WIRE)-Eagle Pharmaceuticals, Inc. and Flamel Technologies SA (NASDAQ: FLML) today announced that the two companies have entered into a license and development agreement for the development of a Medusa-based hydrogel depot formulation of the small molecule antibiotic, tigecycline. Following the promising results generated in the frame of an initial feasibility study established between Flamel and Eagle Pharmaceuticals, Eagle Pharmaceuticals has (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 ABSTRACT: Functional contributions of cis-regulatory sequence variations to human genetic disease are numerous. For instance, disrupting variations in a HNF4A transcription factor binding site upstream of the Factor IX gene contributes causally to hemophilia B Leyden. Although clinical genome sequence analysis currently focuses on the identification of protein-altering variation, the impact of cis-regulatory mutations can be similarly strong. New technologies are now enabling genome sequencing (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 The head direction (HD) system in mammals contains neurons that fire to represent the direction the animal is facing in its environment. The ability of these cells to reliably track head direction even after the removal of external sensory cues implies that the HD system is calibrated to function effectively using just internal (proprioceptive and vestibular) inputs. Rat pups and other infant mammals display stereotypical warm-up movements prior to locomotion in novel environments, and similar (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 SAN DIEGO-(BUSINESS WIRE)-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has entered into a global licensing agreement with Chiva Pharmaceuticals, Inc. for Fablyn (lasofoxifene), a selective estrogen receptor modulator (SERM) that was approved in the EU in 2009 for the treatment of osteoporosis in post-menopausal women at increased risk of fracture. In return for the license, Ligand will receive $4 million in licensing payments over the next eight months and is (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d095da/global_cardiovascu) has announced the addition of the "Global Cardiovascular Drug Market: Strategic Assessments of Leading Suppliers" report to their offering. Global Cardiovascular Drug Market: Strategic Assessments of Leading Suppliers This 1,353 pages report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 The primary objective was to evaluate the long-term safety of desvenlafaxine (administered as desvenlafaxine succinate) during open-label treatment in adult outpatients with a primary DSM-IV diagnosis of major depressive disorder (MDD). |-| Prim Care Companion CNS Disord. |-| Tourian KA, Pitrosky B, Padmanabhan SK, Rosas GR. |-| Wyeth Pharmaceuticals France, Paris (Drs Tourian and Pitrosky); and Pfizer, Collegeville, Pennsylvania (Drs Padmanabhan and Rosas). text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/71299c/top_100_pharmaceut) has announced the addition of Plimsoll Publishing Ltd.'s "Top 100 Pharmaceutical Manufacturers (Global)" report to their extensive range of pharmaceutical publications. The latest report from Plimsoll Publishing is an in-depth financial evaluation of the top 100 pharmaceutical companies in the world. Using the unique Plimsoll method of analysis, each of the global top 100 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/cc678b/global_cns_drug_ma) has announced the addition of the "Global CNS Drug Market: Strategic Assessments of Leading Suppliers" report to their offering. Global CNS Drug Market: Strategic Assessments of Leading Suppliers This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global CNS Market. The report provides a (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/26445b/global_infectious) has announced the addition of the "Global Infectious Disease Drug Market: Strategic Assessments of Leading Suppliers" report to their offering. Global Infectious Disease Drug Market: Strategic Assessments of Leading Suppliers This report provides industry executives with strategically significant competitor information and analysis of the leading players in the Global Infectious (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 In the case of an intellectually disabled patient, the attending physician was restricted from writing a Do-Not-Resuscitate (DNR) order. Although the rationale for this restriction was to protect the patient from an inappropriate quality of life judgment, it resulted in a worse death than the patient would have experienced had he not been disabled. Such restrictions that are intended to protect intellectually disabled patients may violate their right to equal treatment and to a dignified (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=97 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/296c09/north_american_pha) has announced the addition of the "North American Pharmaceutical Market: Strategic Assessments of Leading Suppliers" report to their offering. North American Pharmaceutical Market: Strategic Assessments of Leading Suppliers This report provides industry executives with strategically significant competitor information and analysis of the leading players in the North American (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 A bioequivalence study for venlafaxine generic formulation was conducted as an open label, balanced, randomized, two-way crossover, single-dose study. In this study, a comparison of various pharmacokinetic parameters of venlafaxine hydrochloride 150 mg modified release capsules of Ranbaxy and EFEXOR-XR 150 mg capsules of Wyeth, in healthy, adult, male, human subjects under fasting condition was performed to conclude bioequivalence. Venlafaxine and its major active metabolite (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=97 The pharmacokinetic parameters of tigecycline were assessed in subjects with severe renal impairment (creatinine clearance text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=97 United States Patent: 8026276 |-| Title: Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |-| Inventors: Rubino; Joseph T. (Towaco, NJ), Siskavich; Victoria (Lyon Mountain, NY), Harrison; Maureen M. (Sugar Loaf, NY), Gandhi; Pooja (Highland Mills, NY) |-| Assignee: Wyeth LLC (Madison, NJ) |-| Parenteral formulations of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl) -2-methylpropionic acid (CCI-779) are provided. One parenteral formulation contains (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=97 CAMBRIDGE, Mass.-(BUSINESS WIRE)- Eleven Biotherapeutics, a biopharmaceutical company focused on engineering and developing innovative protein-based therapeutics, today announced the appointment of industry veteran Abbie Celniker, Ph.D., as chief executive officer. Most recently, Dr. Celniker served as president and chief executive officer at Taligen Therapeutics, where she was instrumental in building the company to its acquisition by Alexion in January 2011. œEleven Biotherapeutics (…)